Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy
Open Access
- 5 December 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 25 (3), e528-e535
- https://doi.org/10.1634/theoncologist.2019-0751
Abstract
Background. Sarcopenia and inflammation have been associated with poor survival in patients with cancer. We explored the combined effects of these variables on survival in patients with cancer treated with immunotherapy. Methods. We performed a retrospective review of 90 patients enrolled on immunotherapy‐based phase I clinical trials at Emory University from 2009 to 2017. Baseline neutrophil‐to‐lymphocyte ratio, monocyte‐to‐lymphocyte ratio, and platelet‐to‐lymphocyte ratio (PLR) were used as surrogates of inflammation. The skeletal muscle index (SMI) was derived from the skeletal muscle density calculated from baseline abdominal computed tomography images. Optimal cutoffs for continuous inflammation biomarkers and SMI were determined by bias‐adjusted log‐rank test. A four‐level risk stratification was used to create low‐risk (PLR p < .001; HR, 5.32; CI, 1.96–14.43; p = .001; and HR, 4.01; CI, 1.66–9.68; p = .002, respectively) and progression‐free survival (HR, 12.29; CI, 5.15–29.32; p < .001; HR, 3.51; CI, 1.37–9.02; p = .009; and HR, 2.14; CI, 1.12–4.10; p = .022, respectively) compared with low‐risk patients. Conclusion. Baseline sarcopenia and elevated inflammatory biomarkers may have a combined effect on decreasing survival in immunotherapy‐treated patients in phase I trials. These data may be immediately applicable for medical oncologists for the risk stratification of patients beginning immunotherapeutic agents. Implications for Practice. Sarcopenia and inflammation have been associated with poor survival in patients with cancer, but it is unclear how to apply this information to patient care. The authors created a risk‐stratification system that combined sarcopenia and platelet‐to‐lymphocyte ratio as a marker of systemic inflammation. The presence of sarcopenia and systemic inflammation decreased progression‐free survival and overall survival in our cohort of 90 patients who received immunotherapy in phase I clinical trials. The data presented in this study may be immediately applicable for medical oncologists as a way to risk‐stratify patients who are beginning treatment with immunotherapy.Keywords
Funding Information
- National Institutes of Health/National Cancer Institute (P30CA138292)
This publication has 37 references indexed in Scilit:
- Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-AnalysisJNCI Journal of the National Cancer Institute, 2014
- Obesity and cancer pathogenesisAnnals of the New York Academy of Sciences, 2014
- Definition and classification of cancer cachexia: an international consensusThe Lancet Oncology, 2011
- Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instabilityCarcinogenesis: Integrative Cancer Research, 2009
- Sarcopenia is prevalent in patients with Crohnʼs disease in clinical remissionInflammatory Bowel Diseases, 2008
- Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experienceBritish Journal of Cancer, 2008
- Cancer cachexia syndrome in head and neck cancer patients: Part I. Diagnosis, impact on quality of life and survival, and treatmentHead & Neck, 2007
- The Hallmarks of CancerCell, 2000
- The American Cancer Society challenge goalsCancer, 1999
- Prognostic effect of weight loss prior tochemotherapy in cancer patientsAmerican Journal Of Medicine, 1980